Antitumor effect of a novel nuclear factor-κB activation inhibitor in bladder cancer cells

Expert Review of Anticancer Therapy

Volumn 3, Issue 6, 2003, Pages 793-798

  Horiguchi, Yutaka ^a   Kuroda, Kenji ^a   Nakashima, Jun ^a   Murai, Masaru ^a   Umezawa, Kazuo ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Apoptosis; Bladder cancer; NF B

Indexed keywords

5 DEHYDROXYMETHYLEPOXYQUINOMICIN C; ANTIINFLAMMATORY AGENT; CYCLOHEXANONE DERIVATIVE; CYTOKINE; CYTOTOXIC AGENT; DEXAMETHASONE; I KAPPA B; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL VIABILITY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; GENE CONTROL; HUMAN; MALIGNANT TRANSFORMATION; PARANEOPLASTIC SYNDROME; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN INDUCTION; REVIEW;

EID: 0346328321     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.6.793     Document Type: Review

References (52)

1. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 274, 782-784 (1996).
2. Wang CY, Mayo MW, Baldwin AS Jr. TNF and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274, 784-787 (1996).
3. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science 274, 787-789 (1996).
4. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J. Clin. Invest. 107, 241-246 (2001).
5. Orlowski RZ, Baldwin AS Jr. NF-κB as a therapeutic target in cancer. Trends Mol. Med. 8, 385-389 (2002).
6. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity. J. Biol. Chem. 276, 22382-22387 (2001).
7. Adams J, Palombella VJ, Sausville EA et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59, 2615-2622 (1999).
8. Matsumoto N, Iinuma H, Sawa T et al. Epoxyquinomicins A, B, C and D, new antibiotics from Amycolatopsis. II. Effect on Type II collagen-induced arthritis in mice. J. Antibiot. (Tokyo) 50, 906-911 (1997).
9. Erkel G, Anke T, Sterner O. Inhibition of NF-κB activation by panepoxydone. Biochem. Biophys. Res. Commun. 226, 214-221 (1996).
10. Matsumoto N, Ariga A, To-e S et al. Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C. Bioorg. Med. Chem. Lett. 10, 865-869 (2000).
11. Ariga A. Namekawa J, Matsumoto N, Inoue J, Umezawa K. Inhibition of tumor necrosis Factor-α-induced nuclear translocation and activation of NF-κB by dehydroxymethylepoxyquinomicin. J. Biol. Chem. 277, 24625-24630 (2002).
12. Jamel A. Murray T, Samuela A et al. Cancer statistics, 2003. CA Cancer J. Clin. 53, 5-26 (2003).
13. Ratliff TL, Gillen D, Catalona WJ. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J. Urol. 137, 155-158 (1987).
14. Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK. BCG intravesical instillations: recommendations for side effects management. Eur. Urol. 37(Suppl. 1), 33-36 (2000).
15. Lyons D, Miller I, Jeffers A. Systemic hypersensitivity reaction to intravesical BCG. Scott. Med. J. 39, 49-50 (1994).
16. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with initerferon-α2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J. Urol. 166, 1300-1304 (2001).
17. Gomella LG, Mastrangelo MJ, McCue PA et al. Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J. Urol. 166, 1291-1295 (2001).
18. Pagliaro LC, Keyhani A, Williams D et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a Phase I study of p53 gene therapy. J. Clin. Oncol. 21, 2247-2253 (2003).
19. Waidelich R. Stepp H, Baumgartner R et al. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol. 165, 1904-1907 (2001).
20. Lowe BA, Mershon C, Mangalik A. Paraneoplastic neurological syndrome in transitional cell carcinoma of the bladder. J Urol. 147, 462-464 (1992).
21. Satoh H, Abe Y, Katoh Y et al. Bladder carcinoma producing granulocyte colony-stimulating factor: a case report. J. Urol. 149, 843--845 (1993).
22. Hirasawa K, Kitamura T, Oka T, Matsushita H. Bladder tumor producing granulocyte colony stimulating factor and parathyroid hormone related protein. J. Urol. 167, 2130 (2002).
23. Miller JI, Sarver RG, Drach GW. Leukemoid reaction: a rare paraneoplastic syndrome associated with advanced bladder carcinoma. Urology 44,444- 446 (1994).
24. Steube KG, Meyer C, Tachibana M, Murai M, Drexler HG. Bladder carcinoma cell line KU-19-19-derived cytokines support proliferation of growth factor-dependent hematopoietic cell lines: modulation by phorbol ester, interferon-γ and interleukin-1β. Biochem Biophys. Res. Commun. 242, 497-501 (1998).
25. Kaashoek JG, Mout R, Falkenburg JH et al. Cytokine production by the bladder carcinoma cell line 5637: rapid analysis of mRNA expression levels using a cDNA-PCR procedure. Lymphokine Cytokine Res. 10, 231-235 (1991).
26. Tachibana M, Miyakawa A, Tizaki H et al. Autocrine growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor. Cancer Res. 55, 3438-3443 (1995).
27. Tachibana M, Miyakawa A, Nakashima J et al. Constitutive production of multiple cytokines and a human chorionic gonadotrophin β-subunit by a human bladder cancer cell line (KU-19-19): possible demonstration of totipotential differentiation. Br. J. Cancer 76, 163-174 (1997).
28. Sumitomo M, Tachibana M, Ozu C et al. Induction of opoptosis of cytokine-producing bladder cancer cells by adenovirus-mediated IκBα overexpression. Hum. Gene Ther. 10, 37-47 (1999).
29. Baeuerle PA, Baltimore D. NF-κB: ten years after. Cell 87, 13-20 (1996).
30. Sato K. Terada K, Sugiyama T et al. Granulocyte colony-stimulating factor produced by bladder carcinoma of a patient with leukemoid reaction did not affect proliferation of the tumor cells. J. Urol. 151, 1687-1690 (1994).
31. Demetri GD, Zenzie BW, Rheinwald, JG, Griffin JD. Expression of colony-stimulating factor genes by normal human mesothelioma cells and human malignant mesothelioma cells lines in vitro. Blood 74, 940-946 (1989).
32. Lilly MB, Devlin PE, Devlin JJ, Rado TA. Production of granulocyte colony-stimulating factor by a human melanoma cell line. Exp. Hematol. 15, 966-971(1987).
33. Tweardy DJ, Cannizzaro LA, Palumbo AP et al. Molecular cloning and characterization of a cDNA for human granulocyte colony-stimulating factor (G-CSF) from a glioblastoma multiforme cell line and localization of the G-CSF gene to chromosome band 17q21. Oncogene Res. 1, 209-220(1987).
34. Bussolino F, Wang JM, Defilippi P et al. Granulocyte- and granulocyte macophage colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature 337, 471-473 (1989).
35. Avalos BR, Gasson JC, Hedvat C et al. Human granulocyte colony-stimulating factor: biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines. Blood 75, 851-857 (1990).
36. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46, 705-716 (1986).
37. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Ann. Rev. Immunol. 12, 141-179 (1994).
38. Baeuerle PA IκB-NF-κB structures: at the interface of inflammation control. Cell 95, 729-731(1998).
39. Carswell EA. Old LJ, Kassel RL et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA 72, 3666-3670 (1975).
40. Old LJ. Tumor necrosis factor (TNF). Science 230, 630-632 (1985).
41. Cleveland JL, Ihle JN. Contenders in FasL/TNF death signaling. Cell 81, 479-482 (1995).
42. Hsu H, Xiong J, Goeddel DV. The TNF receptor I -associated protein TRADD signals cell death and NF-κB activation. Cell 81, 495-504 (1995).
43. Li Q, Lu Q, Hwang JY et al. IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev. 13, 1322-1328 (1999).
44. Ozes ON, Mayo LD, Gustin JA et al. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401, 82-85 (1999).
45. Romashkova JA, Makarov SS. NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401, 86-90 (1999).
46. Umezawa K, Chaicharoenpong C. Molecular design and biological activities of NF-κB inhibitors. Mol. Cells 14, 163-167 (2002).
47. Muenchen HJ, Lin DL, Walsh MA, Keller ET, Pienta KJ. Tumor necrosis factor-α-induced. apoptosis in prostate cancer cells through inhibition of nuclear factor-κB by an IκBα 'super-repressor'. Clin. Cancer Res. 6, 1969-1977 (2000).
48. Auphan N, DiDonato, JA. Rosette C, HeImberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 270, 286-290 (1995).
49. Kopp E, Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science 265, 956-959 (1994).
50. Cook GP, Hampton JA. Effects of ibuprofen on the in vitro invasiveness of a human transitional cell carcinoma. Anticancer Res. 17, 365-368 (1997).
51. Miyajima A, Kosaka T, Seta K et al. Novel nuclear factor κB activation inhibitor prevents inflammatory injury in unilateral ureteral obstruction. J. Urol. 169, 1559-1563 (2003).
52. Kikuchi E, Horiguchi Y, Nakashima J et al. Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice. Cancer Res. 63, 107-110 (2003).